Fig. 1
Proportion of participants with viraemic and cleared hepatitis C infection among anti-HCV positive participants, DRUCK study (2011–2014, N = 1.361) and DRUCK 2.0 study (2021–2022, N = 432)
Fig. 1 | Harm Reduction Journal